SecBot SecBot
PRESS-RELEASE ·Filed Aug 6, 2026

TARS

Tarsus Pharmaceuticals, Inc
NEUTRAL
Impact 6/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

The long data timeline (H2 2029) limits near-term catalysts, but the deal expands Tarsus' retina pipeline with a potentially blockbuster orphan drug. Watch for HSR clearance and any competitive Stargardt pipeline updates; near-term stock movement likely driven by financing details and investor reception of the upfront cash/stock mix.

DirectionNeutral
Confidencemedium
Horizonmonths

ALK-001

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
Next catalyst
None dated

What to watchALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$65.33
T+0 close · Aug 6, 2026 · via day close
Latest settled
+14.57%
T+60 · $74.85
Vs SPY
+16.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $65.33entry
  2. T+1 · 3mo ago −0.83%α −1.44% · $64.79
  3. T+5 · 3mo ago +5.43%α +4.22% · $68.88
  4. T+20 · 3mo ago +27.36%α +26.76% · $83.21
  5. T+60 · 18d ago +14.57%α +16.24% · $74.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to $350M in milestones, adding the Phase 3 Stargardt disease candidate gildeuretinol (ALK-001). The deal weds a promising but early-stage asset with no approved therapy today against Tarsus' existing retina capabilities, and top-line data is not expected until H2 2029. The acquisition is accretive to Tarsus' pipeline but adds significant execution risk and a long timeline.

Key Financial Metrics

Deal Value
$800.0M

Key Facts

  • Upfront consideration: ~$450 million ($270M cash + $180M Tarsus common stock at $61.38/share).
  • Milestones: up to $350 million upon regulatory approval and first commercial sale.
  • Royalties: low single-digit tiered descending on gildeuretinol net sales.
  • Phase 3 NORTHSTAR trial (enrolling ~230 patients) topline data expected H2 2029.
  • Stargardt disease has ~36,000 clinically diagnosed patients in the U.S. with no FDA-approved therapy.
  • Gildeuretinol has Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations.
  • TEASE-1 data: 29.5% slower annualized growth rate of atrophic lesions (p<0.001) vs untreated arm; 87% less likely to experience significant low-light vision loss.
  • Transaction approved by both boards and Alkeus stockholders; expected to close in 2026.
  • Tarsus' pipeline includes XDEMVY (approved), TP-04 (Phase 2), TP-05 (Phase 2), and IRX-101 (Phase 2).

Financial Impact

$450M upfront plus up to $350M in regulatory/milestone payments; low single-digit royalties on net sales

cashdilutionr&d_expensepotential_revenue

Risk Factors

  • Phase 3 failure risk (Stargardt trials are notoriously difficult to read on endpoints)
  • Dilution from ~$180M stock issuance (2.93M shares at $61.38, ~6% of current shares outstanding if pre-money ~48M shares)
  • Long timeline (H2 2029) with no near-term revenue from gildeuretinol
  • Integration risk and cash burn ($270M upfront depletes Tarsus' cash reserves)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3340125

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026